Phase II Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2018
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 01 Dec 2017 Planned End Date changed from 1 Apr 2024 to 1 Nov 2023.
- 01 Dec 2017 Planned primary completion date changed from 1 Apr 2024 to 1 Nov 2023.
- 01 Dec 2017 Status changed from not yet recruiting to recruiting.